Inscripta ships benchtop CRISPR platform, raises $150M

By The Science Advisory Board staff writers

April 5, 2021 -- Inscripta has shipped its first Onyx platform for benchtop genome engineering and also closed $150 million in financing.

The Onyx platform is a benchtop system for scalable digital genome engineering and consists of a benchtop instrument, consumables, software, and assays. The fully automated CRISPR workflow allows parallel, trackable editing of single cells, the company said. The first organization to receive the Onyx platform is GeneMill, a synthetic biology foundry at the University of Liverpool.

Inscripta's Onyx platform is a benchtop system for scalable digital genome engineering. Image courtesy of Inscripta.

Funds from the $150 million series E financing round will be used to create CRISPR-based technology from the company's intellectual property portfolio, which includes nearly 100 issued U.S. patents, according to Inscripta. The financing round was led by Fidelity.

Copyright © 2021

Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter